DİLAY KARABULUT CENNET YILDIZ UMUT KARABULUT ERSAN OFLAR FATMA NİHAN TURHAN ÇAĞLAR KADRİYE KART YASAR GÜLÇİN ŞAHİNGÖZ ERDAL OSMAN PİRHAN PINAR KASAPOĞLU NİLGÜN IŞIKSAÇAN
Experimed - 2023;13(3):180-186
Objective: This study aimed to evaluate cardiac myosin-binding protein C (cMyBP-C) levels in patients with COVID-19. Materials and Methods: Overall, 187 patients were enrolled in the study. Patients with mildmoderate and severecritical illness constituted groups 0 and 1, respectively. Results: Admission to the intensive care unit and hospitalization period were significantly higher in group 1. Hemoglobin levels, lymphocyte count, and albumin levels were significantly lower, and lactate dehydrogenase, C-reactive protein (CRP), D-dimer, cardiac troponin I (cTnI), and procalcitonin levels, prothrombin time (PT), and CRP/lymphocyte ratio were higher in group 1 patients compared to group 0 patients. cTnI and CRP/lymphocyte ratio were higher, and ferritin/procalcitonin and albumin/CRP ratios were lower in deceased patients than in surviving patients, while MyBP-C levels were similar in the two groups. Multivariate regression analysis revealed that lymphocyte count and urea levels were independent predictors of mortality. Receiver Operating Characteristic (ROC) curve analysis showed that cTnI level and ferritin/procalcitonin, CRP/lymphocyte, and albumin/CRP ratios were valuable biochemical parameters for predicting mortality in patients with COVID-19. Conclusion: cMyBP-C level may not be a valuable tool for predicting the severity or prognosis of COVID-19.
